Lauren Dembeck

Neoadjuvant treatment with the PARP inhibitor (PARPi) niraparib combined with the anti–PD-1 antibody dostarlimab achieved a 50% pathologic complete response (pCR) rate in patients with germline BRCA –mutated triple-negative breast cancer (TNBC), according to results from the phase 2 TBCRC 056 trial presented at the San Antonio Breast Cancer Symposium (SABCS) 2025. The chemotherapy-free regimen also produced a rapid and significant increase in stromal tumor-infiltrating lymphocytes (sTILs), supporting an immune-priming effect of PARP inhibition in this setting.

Hospital-acquired RSV drives a disproportionate share of pediatric deaths—far deadlier than community-acquired infections.

HIV drug resistance is common across sub-Saharan Africa, with new population-level data showing that more than one in three people on antiretroviral therapy (ART) carried at least one resistance-associated mutation between 2015 and 2019, according to a new analysis published in BMC Public Health. The findings underscore the critical importance of viral load suppression, ART adherence, and country-specific programmatic factors in shaping resistance risk.

Behavioral therapies, especially those classed as brain-gut behavior therapy, significantly improve global symptoms in adults with irritable bowel syndrome (IBS), according to a large network meta-analysis published in The Lancet Gastroenterology & Hepatology.

Recombinant von Willebrand factor (rVWF) provides effective and reliable perioperative hemostatic control for adults with von Willebrand disease (VWD), according to new research published in the European Journal of Haematology.

A novel patient-reported outcome tool designed to capture home-managed sickle cell pain crises (SCPC) demonstrated strong content validity in adolescents and adults with sickle cell disease (SCD), according to research published in Advances in Therapy. The newly developed eDiary captures the frequency, severity, and functional impact of pain crises, addressing a longstanding gap in standardized tools for assessing patient experiences outside clinical settings.

Infectious complications, including endemic opportunistic infections, remain a significant risk following CD19-directed chimeric antigen receptor (CAR) T-cell therapy, according to a real-world cohort study published in Blood Global Hematology. The findings underscore the need for region-specific post-CAR T surveillance strategies.

A novel patient-reported outcome tool designed to capture home-managed sickle cell pain crises (SCPC) demonstrated strong content validity in adolescents and adults with sickle cell disease (SCD), according to research published in Advances in Therapy. The newly developed eDiary captures the frequency, severity, and functional impact of pain crises, addressing a longstanding gap in standardized tools for assessing patient experiences outside clinical settings.

A shortened, outpatient blinatumomab regimen incorporating vial-sharing strategies and resulting in substantial cost savings appears to be safe and feasible in children with relapsed or refractory (R/R) B-cell acute lymphoblastic leukemia (ALL) in resource-limited settings, according to a retrospective study published in JCO Global Oncology.

Late acute and chronic graft vs host disease (GVHD) remain frequent complications and continue to drive long-term mortality following allogeneic hematopoietic cell transplantation (HCT), according to a 10-year follow-up study from the Chronic GVHD Consortium published in